Catalan pharmaceutical giant Grifols sees a 23% jump in net profit in the first half of 2014

July 31, 2014 09:29 PM | ACN / Neringa Sinkeviciute

During the first half of the year, the revenues of the Catalan multinational pharmaceutical company Grifols rose by 16.7% to €1.61 bilion, 75% of which came from the Bioscience division and 18% from Diagnostic. Compared to the first quarter, the proportion of total sales generated by each of the group’s divisions remains unchanged after the acquisition of Novartis' diagnostic business. The world´s third-largest blood-derivate product maker, Grifols obtained a net profit of €224.8 million, 23% more compared with the same period last year, as reported by the company to the Spanish Stock Exchange Authority (CNMV). These positive figures were achieved due to the maintenance of financial costs, made possible by improved financial conditions, despite having increased debt in absolute terms.

Catalonia, a hub of global biomedical research

July 25, 2014 12:32 PM | Bryony Clarke

Catalonia has established a reputation as a global centre of scientific excellence, pioneering research and innovative ideas. This corner of Europe, with just 0.1% of the world’s population, accounts for nearly 1% of global scientific production. The Catalan Research system, formed of 12 internationally esteemed universities, over 60 research centres, 15 world class hospitals, and almost 9,000 innovative companies, attests to the Catalonia's ambitions in science. This territory is also a magnet of international funding: with 1.5% of Europe’s population, it receives 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants. There can be no doubt that Catalonia is now a benchmark in Southern Europe, producing frontier research and punching considerably above its weight in terms of scientific contribution.  It is attracting worldwide talent and projects, and many consider it to be fast becoming the Palo Alto of biomedical research.